Scientists, doctors and other health professionals from the HIV Vaccine Trials Network (HVTN) will present research findings and other HIV-related news at AIDS 2022, the International AIDS Conference taking place virtually and in person in Montreal, Canada, July 29 to Aug. 2.
In a presentation today at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research. NIAID is part of the National Institutes of Health.
Texas Biomed has received a $3.9 million NIH grant to explore how gene-editing technology may help eradicate HIV in the brain.
Background: Online support groups provide opportunities for individuals affected by HIV and AIDS to seek information, advice, and support from peers. However, whether and how engagement with online support groups helps individuals af...
Background: The growth in mobile technology access, utilization, and services holds great promise in facilitating HIV prevention efforts through mobile health (mHealth) interventions in Malaysia. Despite these promising trends, there...
Background: The HIV epidemic has revealed considerable disparities in health among sexual and gender minorities of color within the Unites States, disproportionately affecting cisgender men who have sex with men (MSM) and trans women...
Researchers at the Case Western Reserve University School of Dental Medicine will use a $3.25 million grant from the National Institutes of Health (NIH) to better understand how HIV impacts the human body, from mouth lesions to oral cancer.
.png&width=400&height=400)
Human immunodeficiency virus 1, more commonly known as HIV-1, is known for its uncanny ability to evade the immune system.
Rutgers researchers enable visualization of a transient molecule that helps HIV spread.
UC San Diego researchers have created a mathematical model to help predict risk of anal cancer in persons with HIV infection and aid patients and doctors regarding screening decisions.
HIV has an “early and substantial” impact on aging in infected people, accelerating biological changes in the body associated with normal aging within just two to three years of infection.
Wistar announces that for the first time it will globally stream its 26th Annual Jonathan Lax Memorial Award Lecture, celebrating 26 years of providing state-of-research updates to the community, on Tuesday, June 28 from 9:30 to 11:00 a.m. EST.
Many male couples in the U.S. seem to be underestimating the effectiveness of HIV pre-exposure prophylaxis (PrEP) for HIV prevention, and educating partners together could improve the number of male couples who decide to adopt PrEP. These conclusions come from a study reported in the July/August issue of The Journal of the Association of Nurses in AIDS Care (JANAC), the official journal of the Association of Nurses in AIDS Care. JANAC is published in the Lippincott portfolio by Wolters Kluwer.
Kelly Dooley, MD, PhD, MPH, has been appointed professor and Addison B. Scoville Jr. Chair in Medicine and director of the Division of Infectious Diseases in the Department of Medicine at Vanderbilt University Medical Center, effective Sept. 12. Dooley comes to Vanderbilt from The Johns Hopkins School of Medicine in Baltimore, Maryland, where she is professor of Medicine, and Pharmacology and Molecular Sciences.
Here are some of the latest articles that have been added to the Aging channel on Newswise, a free source for journalists.
Finding suggests that all people with HIV might benefit from additional dose in primary vaccination.
Monkeypox is a zoonotic disease, i.e. it can be transmitted between animals and humans via direct or indirect contacts. Following the eradication of smallpox and the end of universal smallpox vaccination, monkeypox is currently the most prevalent orthopoxvirus infection in humans [1].
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.
SEATTLE (May 18, 2022) – Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at HelpEndHIV.org.
Background: Gay, bisexual, and other men who have sex with men (GBMSM) are at disproportionately higher risk of acquiring HIV and other sexually transmitted infections (STI). While HIV/STI testing rates among GBMSM are increasing wor...
A new software tool makes it easier to study relationships between a host, its microbiome and pathogens like HIV or SARS-CoV-2.
The National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine a five-year, $11.3 million grant to renew the Einstein-Rockefeller-CUNY Center for AIDS Research (ERC-CFAR) and expand its efforts to prevent, treat and cure HIV infection, and thereby reduce the burden of HIV, locally, nationally, and internationally.
The American Society for Clinical Investigation (ASCI) elected Mohammad Sajadi, MD, Professor of Medicine in the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) as a 2022 member.
What: Pediatric Academic Societies (PAS) 2022 Meeting When: April 21 to 25 Where: Colorado Convention Center (700 14th St., Denver, CO 80202)
University of Maryland School of Medicine (UMSOM)’s Institute of Human Virology (IHV) researchers received funding from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) for $2.7 million to study genetic changes in two genes from the HIV-1 virus that may make it resistant to antiretroviral therapy.
SEATTLE — April 6, 2022 — Below are summaries of recent Fred Hutchinson Cancer Research Center research findings and other news. If you’re covering the American Association of Cancer Research’s annual meeting, April 8-13, see our list of Fred Hutch highlights for AACR and contact [email protected] for help setting up interviews with experts.
Here are some of the latest articles that have been added to the Clinical Trials channel on Newswise.
A comprehensive look at all of the active clinical trials on new CRISPR-based genome editing therapies in 2022, and perspective on what is coming next.
As syphilis cases continue to rise across the United States, a new analysis from researchers at the Coalition for Applied Modeling for Prevention (CAMP) offers further insight into racial and ethnic disparities in syphilis rates among heterosexually active women, featuring a new approach to analyzing disease impact.
The National Institute of Mental Health has renewed its support for UCLA’s collaborative Center for HIV Identification, Prevention and Treatment Services, or CHIPTS, with a five-year, $7.5 million grant.
In a JAMA perspective piece, leading infectious disease researchers call for a coordinated response to HIV and COVID-19 globally, building on the successes of key donor programs such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program and Global Fund to Fight AIDS, TB and Malaria (GFATM).
Using mRNA technology like that in the COVID-19 vaccines, researchers have demonstrated a successful way to deliver a potential HIV vaccine, researchers at Duke Human Vaccine Institute report.
The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna. The study evaluates the safety of and immune responses to three different experimental vaccines against HIV. This randomized, open-label trial represents one of the first clinical studies of the use of mRNA vaccine technology against HIV.
Don't miss these articles in our Staff Picks channel
A new study set out to better understand the impacts and trade-offs policymakers must consider when addressing modern infectious diseases and their macroeconomic repercussions.
The three awardees will receive training and mentorship to help support and propel their rising careers in virology
A new University of California, Irvine-led study, called the HOPE (Harnessing Online Peer Education) HIV study, revealed that using peer-led online communities was successful in increasing HIV self-testing and reducing alcohol consumption among Latinx and African American MSM (men who have sex with men).
Some people become seriously ill when infected with SARS-CoV-2 while others have only mild symptoms or no symptoms at all.
Using powerful tools and techniques developed in the field of structural biology, researchers at the University of Washington and The Scripps Research Institute have discovered new details about the human immunodeficiency virus, HIV.
Medication against the nonhuman primate version of HIV given two weeks after infection helped keep tuberculosis in check.
Researchers at UC San Diego School of Medicine have presented data that suggests a new HIV outbreak in Tijuana, Mexico, driven in part by “drug tourism” unabated by the closure of the international border due to the COVID-19 pandemic.
Join the UCLA Fielding School of Public for the 47th Lester Breslow Distinguished Lecture. Dr. Roger Detels — distinguished research professor of epidemiology at the UCLA Fielding School of Public Health and infectious diseases at the David Geffen School of Medicine at UCLA — will present opportunities realized that have contributed to advancing our understanding of disease pathogenesis as well as the shaping of public health policy and promoting of future public health leaders, both nationally and internationally. The event will be hosted by Dr. Ron Brookmeyer, dean of the UCLA Fielding School of Public Health.
Baltimore, Maryland, USA, February 8, 2021: The Global Virus Network (GVN), representing 68 Centers of Excellence and 10 Affiliates in 36 countries comprising foremost experts in every class of virus causing disease in humans, and the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in Durban announced the addition of CAPRISA as GVN’s newest Center of Excellence.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
